drugset / Trial / NCT00174564
EXIBIT: Oxaliplatin in Biliary Tract Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The primary objective is to evaluate the efficacy of the GEMOX treatment as 1st line therapy in patients with advanced biliary tract cancer based on response rate measured by the RECIST unidimensional criteria. Secondary objectives are : Progression free survival, overall survival and safety.
Timeline
- Start
- 2003-04
- Primary completion
- 2006-09
- Completion
- 2006-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Oxaliplatin | Small molecule | — | — |